Fri, Aug 29, 2014, 5:05 AM EDT - U.S. Markets open in 4 hrs 25 mins

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

invst.smrt 22 posts  |  Last Activity: Jun 12, 2014 1:34 PM Member since: Apr 18, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    I M OUT at $5.30

    by cytrx_pumpty_dumpty Jun 12, 2014 10:17 AM
    invst.smrt invst.smrt Jun 12, 2014 1:34 PM Flag

    Sure I respect your decision . But one thing I can tell that you will miss 200% upside from this PPS.
    Look for 80% institution holding in next Qtr reporting. A 100% survival advantage in P2 STS will be a historical moment in oncology world , give then STS is such adamant cancer.
    THLD will report their P3 STS results in Q3 , which will most likely fail , then Aldo will be the only hope in market place for STS patients.
    A accelerated approval for first line STS for Aldo is possible based on the P2 results.

    I actually bought more this morning.

  • invst.smrt invst.smrt Jun 12, 2014 2:24 AM Flag

    Read the life science report for NBS. Company is planning to move to P2 , it means results are P1 results are good.

  • Just letting you know. A eye opener article , CYTR is still one of the cheapest biotech in the history at $5.
    Aldo valued at just $150M .....which has potential to replace doxil , doxorubicin , and #$%$ away a large revenue from abraxane ...
    This run-up will lead to CYTR fair valuation , which is around $12.

  • Mind blowing Type 1 diabetes results on June 15th (Sunday) , patients no longer need insulin injections.
    Nobody is taking about this very important platform.
    Next week PPS target $10.

  • Reply to

    All set to breakout to $6.5

    by invst.smrt Jun 11, 2014 3:07 PM
    invst.smrt invst.smrt Jun 11, 2014 3:52 PM Flag

    Those who bought today will be very happy tomorrow.
    More wall street chatter :
    - PFS advantage at 6 month is pointing to a double the survival , i.e 100% OS improvement.
    - P2 OS results may be good enough to get accelerated approval for first line STS.
    - Aldo is next abraxane .......A $60 stock is very much possible in 2-3 year.
    - We might a get unexpected GBM or partnership related news in coming week.

    Breakout to $7 tomorrow.

  • WS Chatter :

    - Baker bros want $5m share of CYTR . They have hard time getting it.
    - Biding war from J&J and CELG may be happening behind the scene.
    - A big analyst house said "This should have been$8 yesterday"

    Those who sold at $4.75 .,.....will regret for rest of their life.

    This stock will give 1000% gain in 2-3 year.
    BUY and HOLD should be strategy with this stock.

  • CYTR is still ridiculously cheap , excluding the 112M cash , entire CYTR platform is valued at just 150M.
    Which is extremely cheap for a P3 drug with a outstanding P2 results and very encouraging safety profile.
    Aldo has potential to replace Doxorubicin and Doxil ........It should be valued a minimum 300M.
    With that PPS should be $8 right now.
    But now , funds are realizing and this stock will take of itself in couple of weeks.

  • Reply to

    Next week will massacre of Shorts.

    by invst.smrt Jun 6, 2014 1:47 PM
    invst.smrt invst.smrt Jun 7, 2014 8:31 PM Flag

    CYTR dose not need any news to go to $8. The fact is Aldo valuation is just $125 , given that CYTR has 112M cash. Aldo could be a minimum $2.5B drug by 2017 , which is around $40 a share ........that is 1000% gain from hair.
    Keep in mind Aldo will be 3 times of dose as well as cycles as compared to Doxil , hence it can potentially generate 9 times revenue compared to Doxil. There will be lot of off label use also.
    Doxil generated 600M in 2013 , hence Aldo can generate $5B revenue / year.
    Bottom like ......This is stock is about to join class of PCYC , MDVN and ACAD.

    Thanks to Adam F. and Richard Pearson for the BS , which allowed smart investors to load at these low prices.

    Breakout triggers when short looses the battle and their stop buy triggers (similar to stop loss for longs when stock goes down) . If this stock cross $4.54 on Monday , then it will breakout to $7.5 range.

  • EOM. More and more long funds are interested CYTR. CYTR will be worth atleast $2.5B in 2016 , which is $50 a share.
    This stock is cheap anywhere below $8 right now.

  • Reply to

    Those who listened to Adam

    by invst.smrt Jun 4, 2014 7:21 PM
    invst.smrt invst.smrt Jun 5, 2014 8:17 PM Flag

    Todays action was indeed good , this is called wealth transfer from retail / trader to big boys. here is how it works.

    1) Shorts are asking MM to allows them to cover at low PPS
    2) Funds wants to load at low PPS , without running up too much.
    3) MM creates a impression as if stock is loosing steam and will fall back.
    4) Today MM snatched share from all short term trader who play for 2-3% profit , a lot of them bought yesterday around 4.3 and sold above 4.4.
    5) Now today very small number of trader bough share at 4.3 range , all of these share are either bought by short of funds.
    6) Once this gaps fills , i.e big guys are loaded , then MM will release the stock to fly like a bird.

    Based on action from past week , this stock is due for very sharp move , i.e 25% and them 15 %.
    It will happen on two consecutive days to scare retail shorts .

  • NBS is going to present Type-1 diabetes data on Jun 15th . This stock recovered with a big bang from low of $4.5 , which means data going to be superb.
    Even if Treg infusion can reduce frequency of Insulin injection by 50% , this stock will rocket to $15+.
    Due to recent run-up in MNKD (Diabetes drug) , market will closely watch any development in diabetes world.

  • Sold MNKD at $5 .....now they are falling into depression .
    Adam / team did the same thing with CYTR .......But you still have chance to load ......as this is going to $15 .
    If you could not load in low 3's then tomorrow might be a little pull-back to shake retails and trader ......Use that opportunity to load .
    Efficacy in GBM will a historical moment .

  • Any pull-back orchestrated by MM is nothing but a buying opportunity .
    This stock will make very sharp move to $6.5 before anybody know.
    Being sidelines is not an option with this stock.
    2H is full of catalyst . This stock will settle around $9 before results. Funds never want retail to buy at low ......All upgrades will come when stock trades at $7 when funds are loaded .
    But smart trader / retails are buying now. You have to play with these moron Hedge funds.

    This is next ACAD.

  • Reply to

    ASCO data .

    by invst.smrt May 30, 2014 3:12 PM
    invst.smrt invst.smrt May 31, 2014 9:36 PM Flag

    Stock chart is indicating major news next week possibly after Jeffery conference.
    Data reporting prior to ASCO was a tell-tell sign that CYTR is is partnership discussion with a big pharma (Likely J&J or CELG) , they had to share the latest data . As per SEC rules , company must share the important data with public before presenting it to potential suitor .
    Look for massive short squeeze next week.

    In addition , CYTR might get an upgrade from Jeffery next week. Irrespective of anything , CYTR is undervalued anywhere below $7.

  • Reply to

    Do you think Cytrx would accept a buyout?

    by nealde123 May 30, 2014 7:49 PM
    invst.smrt invst.smrt May 30, 2014 8:03 PM Flag

    Compete buyout may not happen , but there is very high probability of partnership . Merck partnered with THLD even with inferior data compared to Aldo for STS indication.
    CYTR may want to partnership for STS indication and then use upfront payment to fund other clinical application of linker tech for CRC , Breast cancer , liver cancer etc.

    This stock is not for trading ......this is a true long term buy and hold.
    This could be $60 stock in 2016 if GBM also pans outs.

  • Reply to

    OUR TAKE ON CYTR STORY

    by asicprof Apr 9, 2014 2:00 AM
    invst.smrt invst.smrt May 30, 2014 7:51 PM Flag

    Neal......It does't work this way ......Institution like low risk Bio stock , CYTR is the one of them due to following reasons:

    - Well financed
    - Extremely positive P2 results.
    - FDA blessing on dosing regimen , hence safety is not an issue.
    - Simple and proven science (Abraxane also used Albumin based linker technology).
    - Doxorubicin is time tested for 50 year .

    Institution generally stays away from fancy Bio like stem cell etc.
    CYTR is plain / white .....Bio with very high chance of success .

    This stock will have steady run-up until institution ownership reaches 70%

  • Reply to

    OUR TAKE ON CYTR STORY

    by asicprof Apr 9, 2014 2:00 AM
    invst.smrt invst.smrt May 30, 2014 7:28 PM Flag

    Wall Street

  • Reply to

    ASCO data .

    by invst.smrt May 30, 2014 3:12 PM
    invst.smrt invst.smrt May 30, 2014 3:25 PM Flag

    To be in the position to negotiate with BP . Right now BP needs them , they don't because of cash position .
    I have a feeling , CYTR will also discuss OS trend in P2 trial , which is missing from the previous data release.

    CELG and J&J must be eyeing CYTR closely.

    With GBM data in Q3 , I see PPS blasting to 12 + in relatively short order.

  • invst.smrt by invst.smrt May 30, 2014 3:12 PM Flag

    It was quite unusual for company to release data just 2 days before ASCO presentation.
    It seems company is in partnership discussion with a big pharma . They are obliged to share the data with public before presenting it to potential suitor .

    We might hear a partnership announcement after Jeffery presentation on Jun -2.
    A 100M upfront payment with a milestone payment up to 1B is very much possible.

    PPS chart is showing a overshoot to $7.5 next week.

  • and NBS acquired CSC, this time I bet partnership with Baxter is coming very soon.

SNTA
4.03-0.04(-0.98%)Aug 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.